Stocks

Keros Therapeutics KROS

Health care sectorNasdaq

What to see in Keros Therapeutics now

Is Wall Street adding or cutting?−19

132 13F filers hold it · −19 against the quarter before · shares held +7.4%

Holdings of 06/30
Who bought more than 5%?8.4%

BlackRock holds 8.4% · −1.7pp on the report before

Filed 07/29
What comes next?10/13 (Tue)

10/13 estimated earnings

Due 10/13

Company

Exchange
Nasdaq
Industry
Pharmaceutical Preparations
Headquarters
Lexington, Massachusetts
Fiscal year end
12/31
Next earnings
10/13, estimated
  • 10/13 estimated earningsDue 10/13
Exchange
Nasdaq
Headquarters
Massachusetts
SIC code
Pharmaceutical Preparations
Fiscal year end
12/31
CEO pay (proxy)
$2.5M · year ended 25/12/31
CEO pay actually paid
$3.7M · year ended 25/12/31
Next earnings (estimated)
10/13
Last earnings filing
08/03
Korean holdings rank
Outside the top 50

The next earnings day is estimated from the spacing of the last four quarters' 8-K filings.

Korea Securities Depository · released 09/22

Corporate actions

26-week trading